

## PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : A61L 27/00		(11) International Publication Number: WO 87/ 05521
		(43) International Publication Date: 24 September 1987 (24.09.87)
(21) International Application Number: PCT/US87/00348	(74) Agent: JACKSON, David, A.: 17 Academy Street, Suite 1000, Newark, NJ 07102 (US).	
(22) International Filing Date: 11 March 1987 (11.03.87)	(81) Designated States: AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European patent), FR (European patent), GB (European pa- tent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent).	
(31) Priority Application Number: 838,533		
(32) Priority Date: 11 March 1986 (11.03.86)		
(33) Priority Country: US		
<p>(71) Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US); Adminis- tration Complex, 30 Bergen Street, Newark, NJ 07107-3007 (US).</p> <p>(72) Inventors: PARSONS, John, R.: 185 High Street, Perth Amboy, NJ 08861 (US) ALEXANDER, Harold : 47 Elmwood Place, Short Hills, NJ 07078 (US). WEISS, Andrew, B.: 66 Slope Drive, Short Hills, NJ 07078 (US).</p>		

## Published

With international search report.

Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt  
of amendments.

(54) Title: MOLDABLE BONE IMPLANT MATERIAL

## (57) Abstract

A moldable bone-implant material containing between about 40%-58% hard filler particles and of between 13%-60% of a biocompatible, biodegradable inorganic binder. The binder comprises calcium sulfate hemihydrate. A preferred hard filler is hydroxyapatite. In use, the material is applied under conditions which allow molding and the bone site is filled with the moldable material, which then forms a contour-fitting, semi-rigid implant. The implant retains its contour fit and acquires a rigid final state as the binder in the implant is gradually biodegraded and replaced through tissue ingrowth from the surrounding bone site.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international appli-  
cations under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KF	Democratic People's Republic of Korea	SD	Sudan
CF	Congo	KG	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SI	Slovenia
CH	Switzerland	LU	Luxembourg	SV	Swedish Union
CI	Ivory Coast	MC	Monaco	TD	Chad
DE	Germany, Federal Republic of	MG	Madagascar	TG	Togo
DK	Denmark			US	United States of America
FI	Finland				

# MOLDABLE BONE IMPLANT MATERIAL

The present invention relates to a moldable bone-implant material formed of hard bone graft filler particles bound together into a moldable cohesive mass with a biodegradable substrate.

## Background of the invention

Bone implants are used for bone reconstructive surgery and repair where bone loss or traumatic damage has occurred. In addition to the usual function of strengthening and filling in a repaired bone area, implants can also act to transmit forces to the surrounding bone area, to preserve the vitality of the bone. As an example of the latter function, bone implants are commonly placed in tooth-extraction sites by to help preserve the alveolar bone by providing for continued force on the bone during chewing.

The most proven and accepted synthetic material for bone reconstruction and repair is hydroxylapatite. This material has outstanding biocompatibility, due to its similarity in composition and crystalline structure to the inorganic component of bone. The most important property of hydroxylapatite is its ability to bond directly to bone tissue. Tissue ingrowth into the matrix of the particles acts to stabilize the implant in the surrounding bone and, where the implant is formed of hydroxylapatite particles, forms a tissue matrix which helps maintain the integrity of the implant.

One type of hydroxylapatite implant which has been used heretofore is a rigid implant which is intended to be machined by the surgeon or dentist to fit the implant site. The implant may be formed of a solid dense block or porous block of hydroxylapatite or by binding hydroxylapatite particles with a permanent, rigidifying polymer material.

-2-

Implants of this type suffer from a number of disadvantages. The process of determining the shape of the bone site and fashioning the implant to fit the site is time consuming and complicates the surgery. The implant rarely is ideally shaped and therefore may work loose in the site before tissue ingrowth can occur. Such implants require suturing soft tissue to hold them in place, and may require protecting the site against movement for an extended post-operative period. Also, the implant cannot be fashioned to take advantage of undercut surfaces at the bone site which otherwise might contribute to anchoring the implant. Up to 90% of such implants have been reported to work loose within the first year of implantation.

Implants formed of loose non-bonded hydroxylapatite particles are also well known in the prior art. In preparing an implant of this type, the particles are wet with saline or the patient's blood to give the particles some cohesion and make them manageable during the implant procedure. The loose mass of particulate material is placed in the bone site, where it can adapt to the contours of the surrounding support tissue. After implantation, the particle mass is ingrown with hard or soft tissue which stabilizes the mass of particles, typically in a period of a few days to weeks. The implant can thus acquire a rigid contoured fit, and can also conform to undercut regions in the site to provide increased anchorage.

Despite the advantages of loose-particle implants, a number of problems have been encountered. Loose particles are generally difficult to deliver to the site in a convenient manner, and paraphernalia, such as mixing dishes, applicator funnels, suction devices, and the like, may be required. The particle mass has little cohesive strength and very often loses its shape before the mass is stabilized by tissue ingrowth. For example, particles

-3-

used for rebuilding the alveolar ridge often exhibit ridge flattening and hence a loss of ridge height before the implant particles can be stabilized by tissue ingrowth.

The loose cohesion of the particle mass also allows particles to migrate away from the implant site before tissue ingrowth is complete, and this can result in implant failure and exfoliation of particles into the patient's mouth in the case of oral implants.

#### SUMMARY OF THE INVENTION

10 It is a general object of the invention to provide a bone-implant material which substantially overcomes problems associated with existing solid rigid-block and loose particle types of implant materials.

15 A more specific object of the invention is to provide such material which overcomes the disadvantages of loose-particle implant placement, including loss of implant material and shape, while maintaining the contour-fit and exceptional bone-like and biological ingrowth characteristics of particulate hydroxylapatite.

20 A related object of the invention is to provide such a material which is readily molded to fit the contours and undercut regions of a bone implant site.

25 Still another object of the invention is to provide a method using such material for filling a bone site with a rigid, contour-fitting, hydroxylapatite implant.

30 In accordance with the invention, the binders which can be used in the present moldable bone-implant materials comprise inorganic materials. Inorganic materials can include those materials which when placed in a bone-implant environment (a) are compatible with that environment, (b) undergo biodegradation in that environment to release only biocompatible degradation

-4-

products, and (c) undergo biodegradation at a rate which allows gradual binder replacement in the material by in situ tissue ingrowth over a several-day to several-week period. Among suitable inorganic binders, inorganic

5 cements are preferred, with special preference being given to calcium sulfate hemihydrate as it can consistently yield an implant material which will have the desired moldability properties while allowing gradual binder replacement in the material by in situ tissue ingrowth over a several-day to several-week period. The binder

10 preferably constitutes no more than about one-third of the total solid volume of the material. When the binder biodegrades, its space becomes a void in the material which can accommodate tissue ingrowth. The minimum amount of binder is that necessary to give easy formability and provide sufficient particle cohesion and shape retention

15 and implant strength during the period of tissue ingrowth.

20 In another aspect, this invention provides a storable dry bone-implant material which is made up of the filler particles in admixture with particulate inorganic cement in pre-cure form.

25 In yet another aspect, this invention provides a method of filling a bone site with a contour-fitting rigid particle bone implant. In this method of the invention, the bone-implant material comprises hard filler particles and a binder and is moldable at the conditions and time of implanting. The site is filled with the moldable material

30 to form a contour-fitting implant in the site. Over a period of several days to several weeks or more, the binder undergoes gradual biodegradation and is replaced by ingrowth of surrounding tissue. The moldable implant material may be dispensed from any convenient device or

35 form such as syringe, tube-type dispenser, dish, or in soft block or roll form. The mold-in-place implant substantially retains its contour-fitting shape during the several-day to several-week period when the binder is

-5-

gradually degraded and replaced by tissue ingrowth from the surrounding bone site, to rigidify the implant.

These and other objects and features of the invention will become more fully apparent from the following detailed description of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

##### The Implant Material and Its Preparation

The bone-implant material of the invention is prepared by mixing hard bone-graft filler particles with biocompatible biodegradable binder. The resulting material is moldable, allowing the material to be applied to a bone site in a contour-fitting manner. The terms "biocompatible" and "biodegradable" as used herein have their normal art-accepted meanings, that is, "biocompatible" means that material is compatible with a living animal and in use does not give rise to untoward effects, reactions, toxicity or the like; and "biodegradable" means that a material undergoes an expected breakdown in its physical or chemical structure when exposed to a given biological environment of use.

##### Filler Particles

Any biocompatible inorganic hard filler particles, including autogenous bone chips, can be used in this invention. However, hydroxylapatite is the preferred filler for its permanence and biological profile. Tricalcium phosphate (TCP) and calcium phosphate glass granules may also be used alone or in combination with hydroxylapatite, particularly if some degree of resorption is desired in the filler.

Hydroxylapatite particles are preferably the type of dry free-flowing hydroxylapatite particles supplied for use in

-6-

forming wetted, loose-mass implants, and can be obtained commercially from Orthomatrix Corporation (Dublin, CA) or Calci-tek (San Diego, CA). Particle sizes of between about 250 and 5000 microns are generally suitable and particle sizes between 250 and 2000 microns are preferred, smaller particles showing increased difficulty in allowing tissue ingrowth and larger particles requiring increased quantities of binder for ease of application. As marketed by Orthomatrix Corporation, these particles are supplied as ranges of various sized particles, for example from 250-550 microns (HA-500), 500-1000 microns (HA-1000), and the like. Such mixtures are quite suitable.

##### Binder

The binder used in forming the bone graft material is selected for three important properties: (a) susceptibility to rapid biodegradation, to allow for gradual binder replacement by tissue during tissue ingrowth, without retarding ingrowth; (b) flowability or fluid-flow properties in combination with cohesiveness so as to allow the material to be molded and formed during implantation and achieve a contour fit at the bone site; and (c) biocompatibility, that is, the binder should not provoke a serious inflammatory or other tissue-rejection response, at least within the several-week period when tissue ingrowth replacement is occurring.

For most biodegradable inorganic binders of interest, biodegradation may involve gradual dissolution of a moderately soluble inorganic salt, hydrolysis of bonds within an inorganic structure or ionization of weakly acidic or basic groups within the inorganic material. Preferred binders are those which are degraded to metabolites which are normal to the body or for which the body has effective elimination routes.

-7-

Examples of preferred inorganic binders include the inorganic cements such as the gypsum-based plasters including calcium sulfate hemihydrate (Plaster of Paris), sodium based Mack's cement and the like. These inorganic materials are characterized by forming a cohesive plastic mass when mixed with an aqueous liquid such as water, sterile water, sterile saline, patient's blood or the like, and through hydration taking a "set". Of these materials, calcium sulfate hemihydrate is generally preferred because of its long acceptance. (See, for example, Peltier, Leonard. F. CLINICAL ORTHOPAEDICS, Vol. 21, Pages 1-31, 1961) as a safe restorative material, as well as its properties of being plastic and moldable for useable periods before it "sets up" and of being bioerodible at rates consistent with the biodegradability requirements of this invention. The calcium sulfate hemihydrate can be in either the alpha or beta crystal form. It is readily available commercially such as the material marketed as Durobond Plaster of Paris. More specialized forms of calcium sulfate hemihydrate can be used as well, with special preference being given to materials such as Baker Chemical Company's calcium sulfate hemihydrate which appears to yield a stronger product at lower binder use levels and thus a product with less volume loss as its calcium sulfate is biodegraded.

The moldable, plastic nature of the inorganic binders is advantageous in the present invention for several reasons. The inorganic cement type binders provide implant materials that may be hand formed as a relatively low-viscosity mixture when initially mixed with the aqueous liquid and then shortly thereafter, e.g. in a matter of from 3 to 45 minutes, assume a relatively high viscosity, more rigid shape when the cement sets. These binders allow a cohesive mass of implant material to be formed and used and shaped. This corrects the problems of particle migration which occur when simple suspensions of powders are employed. Also, materials using the inorganic

-8-

cement binders provide plasticity and moldability only during the implantation procedure so that the material, once implanted in a bone site, retains a more rigid, shape-retaining condition.

The binder preferably ranges in fluid-flow properties (flowability) between a highly viscous fluid and a puttylike semi-solid, at the selected conditions of use. With too low a binder viscosity, the implant material suffers the same problems seen in loose-particle implants: poor shape retention, once molded, and poor cohesiveness, leading to exfoliation of particles before or during the tissue ingrowth period.

#### Advantages of the Invention

It is important to recognize that the binders described here do not rely on highly exothermic chemical reactions to produce a rigid mass as is commonly done with thermosetting polymers such as polymethylmethacrylate (PMMA). Thermosetting polymers generally require initiators to catalyze hardening and such reactions are exothermic. Where PMMA is used, it can generate enough heat to damage adjacent tissue. Accordingly, the binders employed in this invention are at most only mildly exothermic when they set up and do not damage adjacent tissue. Thermoset polymers also contain residual unpolymerized monomer which, along with catalyst residue, give material of questionable and variable biocompatibility. Also, the moldability of thermoset binders is time dependent and not reversible, or reformable once hardened.

The implant materials of this invention have the following desirable characteristics:

-9-

1. Formability, moldability - and the ability to completely fill undercut cavities not possible with solid blocks or composites.
2. They are, during application, two phase materials.
3. The binder is biocompatible and biodegradable.
4. The solid particle phase is discontinuous and the size and shape of the solid particles determines and presents a unique pore structure for tissue ingrowth.
5. The binder is the continuous phase.

10 The binder's function is temporary for ease of application of the implant and to hold the particles in place for a limited period after implantation until the binder is replaced by tissue.

15 The binder-containing implant materials are generally formed in two steps. In the first step, the filler particles are blended with a dry particulate form of the binder. In the second step, the dry mixture is mixed with a pharmaceutically acceptable aqueous liquid, most typically sterile water, sterile saline or the patient's blood to yield the desired cohesive, moldable, plastic mass. This material is then applied as the desired implant and allowed to stand for a few minutes, i.e. from about 1 to about 30 minutes, and preferably from about 5 to 30 minutes, during which time it sets or solidifies into a relatively rigid body.

25 The ratio of particles to binder, the amount of aqueous liquid added and the amount of mixing applied can each have an effect on the properties of the moldable plastic implant material and the final "set" product.

-10-

Typically, the proportions of dry filler particles to dry binder ranges from the largest proportion of filler that will give a moldable cohesive product, (generally about 85-90% by weight filler and 10-15% binder) down to the smallest proportion of filler that will give a product that will still deliver an adequate amount of solid filler to the bone area being repaired to achieve the desired repair (generally about 30-40% filler and 60-70% by weight binder). As hydroxylapatite makes up the filler particles, it is of special advantage to use a mixture that provides at least 2/3 of the mixture volume as filler, as this permits the defined level of voids between the filler particles to permit the fortuitous growth of bone tissue into the particle matrix, more preferably so that from 70% to 95% of the volume is hydroxylapatite. A preferred range of proportions of the mixture of hydroxylapatite and calcium sulfate hemihydrate comprises from 85-40% by weight of the former and from 15-60% by weight of the latter. A more preferred set of proportions are hydroxylapatite 55-75% by weight and especially 60-70% by weight, and calcium sulfate 24-45% by weight and especially 30-40% by weight.

The amount of aqueous liquid added to form the plastic mass should be controlled. If the weight of aqueous liquid is substantially greater than about 25% of the weight of filler plus binder, a product will result which is syrup-like and difficult to apply. If the weight of water is as low as 5% or so, the resulting product will not be properly plastic and cohesive, although it may be useable for repairing minor bone defects or holes such as filling tooth extraction sites, or like defects, where it can be tightly packed into the defect and its lack of coherence will not be a critical failing. Preferred aqueous liquid levels are from about 10 to about 22% by weight based on the weight of the dry components, and most preferred aqueous liquid levels range from about 15 to about 20%.

-11-

The mixing time should also be monitored. As a general rule, the longer the mixing time between the aqueous liquid and the dry powders, the shorter the working time before the plastic mixture sets up into its rigid form. Generally, it is not realistic to expect the mixing to be complete in less than about 10 seconds. If it is extended longer than about 2 minutes, this can decrease the set-up time to a minute or two. Best results are generally achieved when the mixing time is from about 15 seconds to about 90 seconds, with special preference being given to mixing times in the range of from about 20 seconds to about 45 seconds.

A detailed description of the preparation and use of the inorganic binder-containing bone implant material of the invention is provided in the Examples, together with data demonstrating its advantageous properties.

After application of the inorganic binder-containing materials to the bone-implant site, it is generally preferred to allow the material to set for a brief period, such as from about 5 minutes to about 30 minutes, so as to allow the binder to fully cure and form a strong rigid body.

As noted previously, the implant materials of this invention may contain other added materials such as markers or the like, if desired.

The bone-implant material may be presterilized by heat, gamma radiation, ethylene oxide, or other available methods. For dispensing, the material can be supplied in a syringe or squeeze-bottle container, allowing direct application of the material into the bone site. Alternatively, the material can be supplied in dish, or flexible roll or block form.

-12-

### Bone Implant Method

This invention includes a method for forming a rigid contour-fitting hard filler implant in a bone site. The method is generally applicable to bone reconstruction or repair needs where a hydroxylapatite or other hard filler bone implant can strengthen a bone region and/or act to transmit stresses to surrounding bone area, to preserve the vitality of bone. Typical applications include replacing damaged or resorbed bone regions, repairing bone fractures, and filling tooth-extraction sites to help preserve underlying alveolar bone. In addition, the method may be used in anchoring a joint-replacement prosthetic device within a suitable bone cavity.

The bone site which is to receive the implant is prepared by conventional surgical techniques. These usually involve exposing and cleaning the bone site, and may require surgical removal of parts of the bone, for example, to form undercuts at the bone site or to shape the site for more favorable implant seating or stress transmission. For attaching a prosthesis which is designed to be anchored to the bone through a stem, the bone is prepared with a suitable stem-receiving cavity. Here the space between the bone cavity and the prosthesis stem forms the bone site which is to be filled with the implant material.

In practicing the invention, there is provided a moldable hydroxylapatite containing bone-implant material of the type above. As described above, inorganic binder-containing implant materials having a range of molding temperatures and conditions and varying rates of biodegradability can be provided, by adjusting the composition and amount of binder in the material. Naturally, it is desirable to use proportions of binder which will assure adequate strength and cohesiveness.

-13-

Also as discussed above, the composition and amount of binder can be adjusted to allow for effective tissue ingrowth in the implant material. For example, if the binder is expected to be degraded only slowly at the bone site, due to lack of enzymes, body fluid flow or the like, it may be advantageous to provide increased void spaces in the material, by reducing the amount of binder.

Similarly, where rapid binder breakdown is expected, a greater amount of binder would be indicated.

10 To prepare the binder-containing bone implant materials of the invention for use, the material is formed into its cohesive moldable form in a suitably sterile mixing zone.

To form the implant, the moldable implant material is applied to the bone site to fill the site in a preferably space-filling manner, producing a contour fit between the bone and implant. For the usual bone reconstruction and repair, the material is applied to the bone surface and pressed into or onto the site to force the material into any surface irregularities of the site, such as cracks, holes, and particularly undercut features. The outer surface of the material is then fashioned to give the bone site the desired surface appearance. The latter process may require filling the site with additional material and/or cutting away originally applied material.

25 In applying the method to a prosthetic attachment, the molded material is applied to the outer surface of the prosthesis stem and/or to the inner surface of the bone cavity, in an amount calculated to fill the space between bone and cavity. The stem is then forced into the cavity until the prosthesis is fully seated in the cavity and the implant material is forced substantially completely into the stem/bone space. Where the stem is relatively long, as is the case with the usual femoral-side hip-joint replacement prostheses, it is generally advantageous to form a biological bond between bone and stem only in the

-14-

proximal region of the stem. In this situation, the bone site to be filled with the implant material would be confined to the proximal stem/bone space.

5 The method of the invention is effective to produce a rigid, contour-fitting implant at the bone site. Unlike solid implants which have been used heretofore, implant rigidity is produced by tissue ingrowth and replacement of binder, and the binder itself only provides initial cohesiveness and semi-rigidity. As mentioned above, the tissue ingrowth typically occurs over about a three day to six-week period, and can involve tissue ingrowth into the void spaces of the material as well as biodegradation of the binder.

15 From the foregoing, it can be appreciated how various objects of the invention are met. The implant material is easily applied in moldable form to a bone site, to provide a contour-fitting implant. The method of filling the bone implant with the moldable material avoids the problems of measuring and shaping a rigid-block implant, leads to a better fit than can be achieved with solid implants, and can take advantage of undercut surfaces within the bone site.

25 At the same time, the material is sufficiently cohesive to resist particle exfoliation during the tissue ingrowth period, and can be made relatively rigid, after cooling, to maintain its contoured shape until it can be rigidified by tissue ingrowth. Through these advantages, the material substantially overcomes problems associated with loose-particle implants.

30 The invention will now be shown in the following Examples. These are presented to illustrate the invention and are not to be construed as limiting its scope.



-15-

EXAMPLE 1

In a representative preparation, hydroxylapatite (Orthomatrix HA 500, 250-500 microns particle size) and calcium sulfate hemihydrate (Durobond Plaster of Paris) are mixed as dry powders in the weight ratio of 65% HA 500 - 35% Durobond until homogeneous. A 3 gram sample of this material is placed into a mixing palette. Sterile saline, 0.48-0.60 cc, is then added and quickly mixed into the powder to give cohesive, moldable, plastic bone-implant material. The material is putty-like in consistency. Mixing is completed in about 30 seconds.

The material is loaded into a syringe using a vibrator.

The syringe is vibrated and its open nozzle is placed in the moldable material. The plunger is withdrawn to draw material into the syringe. The material can then be dispensed into a bone site in need of restoration. After about 5 minutes, the inorganic binder sets up into a somewhat rigid body. Prior to that time, the material can be molded and shaped into the desired contours. After an additional period, the implanted material takes on additional rigidity to serve as a rigid bone implant.

This preparation is repeated numerous times varying the relative proportions of binder and filler, the nature of the binder and the filler, the mixing time, and the nature and amount of added aqueous fluid. The materials so produced are tested to determine their physical properties and the effect of the varied parameters as follows:

A series of mixtures of hydroxylapatite (500-1000 micron size) with calcium sulfate hemihydrate (Durobond-Plaster of Paris) were prepared. The proportions of the two solids were varied from 20% calcium sulfate hemihydrate to 30%, to 35%, to 90%. These mixtures were prepared into moldable bone defect repair materials by adding water, and were cast into 1.25 cm diameter test cylinders for

-16-

compression strength tests. It was seen that the 90% sample failed at a stress of 8.2 MPa, the 40% material had the same strength and the 35% was similar, at 7.4 MPa. The 20% material failed at less than 2 MPa.

5 Repeating, using purer Baker Chemical Company calcium sulfate hemihydrate, 40% and 35% binder content materials had virtually identical compression strengths of about 13.3-13.6 MPa.

10 A similar test with Baker calcium sulfate hemihydrate and hydroxylapatite having a 250-500 micron size showed that at 40% by weight binder, the strength was 10.9 MPa, at 35%, strength was 11.4 MPa while at 30%, strength fell at 6.5 MPa. These values compare favorably with the 7-70 MPa strength range of porous hydroxylapatite and as such, show that the material of this invention can be used in applications which call for porous hydroxylapatite blocks.

15 Either water or saline may be used to wet the mixed calcium sulfate hemihydrate and hydroxylapatite powders without affecting the maximum attainable strength of the cured implant. The difference between the two lies in the mixing/working time constraints. A mixing time of no more than 30 seconds to give a working time of 4 to 10 minutes was typical of the results obtained when sterile saline (0.9%) was used to wet the composite. However, if sterile water was used with a 30 second mixing, the working time ranged from 20 to 30 minutes. The working time could be decreased by increasing the mixing time. Since, sterile saline is readily available, it is the preferred wetting agent. Water may be used where a delayed setting time is desired.

20 A 35% Baker Chemical calcium sulfate hemihydrate-hydroxylapatite composite was allowed to set hard and then the compressive strength of the composite was tested wet, following a soak of a specified number of days. Equally important as the strength was the surface erosion which

-17-

occurred, the number of loose particles resulting from the erosion and the maintenance of the set shape.

Following setting, cylinders of composite were suspended in a flask containing saline at 37°C. The flasks were placed in a shaker bath and the saline was changed every 24 hours. Samples were removed and tested at 1, 2 and 4 days. The results of this testing are shown in the following table.

STRENGTH LOSS ON SOAKING

Days of Soak	Strength MPa	Percentage Original Strength Lost
0	11.4	0
1	8.3	27.2%
2	6.1	53.5%
4	5.2	54.3%

During the first two days, there was a significant drop in strength, after which time, the rate of strength loss significantly decreased. Surface erosion began immediately upon suspension in saline, however, there were very few loose particles until 4 days of soaking had occurred. The set composite maintained its shape throughout the course of the study.

At the end of 4 days, soft tissue ingrowth would be expected to have advanced sufficiently to hold all particles in place, thereby preventing migration.

An In Vitro test of resorption volume was carried out as follows:

A five gram sample of dry (65 wt % HA-500/35 wt % CaSO<sub>4</sub>) was wetted with saline. It was placed into a centrifuge tube and vibrated to remove air bubbles. The five gram

-18-

mixture filled the centrifuge tube to a volume of 2.9 cc. The amount of HA-500 in the five gram HA cement mixture (3.25 grams) was also placed in a centrifuge tube and vibrated to settle the HA particles. The HA particles filled the centrifuge tube to a volume of 2.6 cc. The difference between these two volumes is the actual volume of CaSO<sub>4</sub> present, which is also the actual volume of CaSO<sub>4</sub> present, which is also the total volume of the implant which would resorb. The volume of CaSO<sub>4</sub> is 0.3 cc or 10.3% of the total volume. Therefore, after resorption of the CaSO<sub>4</sub> is complete, only 10.3% of the initial volume will have resorbed. Since tissue infiltration occurs simultaneously with calcium sulfate resorption, it is likely that there would be far less than 10.3% volume loss from the implant site. Thus, the implant site would be expected to maintain its post-operative-contour without a significant collapse.

EXAMPLE II

ANIMAL TESTS

A. Rabbits

Examining the bioresponse to calcium sulfate hemihydrate and hydroxylapatite composites began with a rabbit tibial defect model. Small holes penetrating to the medullary canal were cleaned of debris and left as unfilled controls, or were filled with a paste of HA-Composite, closed and allowed to heal.

The bone was labeled with oxytetracycline before sacrifice at 2 and 4 weeks. The undecalcified sections were photographed with fluorescent light using appropriate filters.

At 2 weeks, empty control holes were incompletely bridged with trabecular bone growth originating mainly from the

endosteum. For the HA-Composite defect, all but the central third of the implant site was bridged with new bone.

At 4 weeks, in the control, trabecular bone bridged the defect at the cortical level only. New bone had not yet invested the central three quarters of the defect site. In contrast, the HA-Composite, in most sections, was completely bridging the defect site, at subcortical levels, with trabecular bone. Although not known with certainty, it appeared that the composite had in fact enhanced the rate of bone growth. Higher magnifications showed the intimate nature of contact between the HA and new bone.

In rabbits, the HA-Composite accelerated trabecular bone bridging of the defect. This could not occur if the material were not biocompatible nor if the calcium sulfate were not easily resorbed and readily replaced by bone.

#### 8. Dogs

This study was designed to ascertain the value of the HA-Composite in maintaining alveolar ridge morphology after tooth extraction. Previous studies had shown that if sufficient HA particles were retained in tooth sockets that ridge maintenance would result. The difficulty has been consistently retaining an adequate fill of particles by preventing particle exfoliation.

Maxillary and mandibular incisors and premolars were extracted from beagle dogs and filled with HA-Composite. Gingiva were approximated with sutures and never completely closed. No significant implant loss was observed for the 96 HA-Composite sites. The gingiva closed over the implant and control sockets within 7-10 days post-operatively. No incidence of inflammation or infection was observed. Gross examination showed

-20-

excellent retention of the implant, bony ingrowth and normal gingiva.

Once applied, the HA/CaSO<sub>4</sub> paste hardened in place in 15-30 minutes. The calcium sulfate gradually degraded in the body and concurrently the HA particles were invaded with tissue.

While particular embodiments of the invention have been described, it will be appreciated that a variety of changes and modifications can be made without departing therefrom.

-21-

WHAT IS CLAIMED:

1. A moldable bone-implant material comprising a cohesive plastic mixture of hard filler particles and a biocompatible, inorganic biodegradable binder.
2. The material of Claim 1, wherein the particles are hydroxylapatite.
3. The material of Claim 1, wherein the binder constitutes less than about one-third of the material's total volume.
4. The material of Claim 3, wherein the binder is biodegradable over a period of about three days to six weeks, with the material operatively placed in a bone site.
5. The material of Claim 4, wherein the binder is an inorganic cement.
6. The material of Claim 5, wherein the inorganic cement comprises calcium sulfate hemihydrate.
7. The material of Claim 1, comprising calcium sulfate hemihydrate and hydroxylapatite in the dry weight proportions of from about 15 to about 60% calcium sulfate hemihydrate and from about 40 to about 85% hydroxylapatite in admixture with sterile, biocompatible aqueous liquid to give a cohesive, moldable mass.
8. The material of Claim 7 wherein the dry weight proportions are from about 30 to about 40% calcium sulfate hemihydrate and from about 70 to about 60% hydroxylapatite.
9. The material of Claim 7 wherein the sterile, biocompatible aqueous liquid is sterile saline.

-22-

10. The material of Claim 7 wherein the sterile, biocompatible aqueous liquid is sterile water.
11. The material of Claim 2 wherein the particles of hydroxylapatite have particle sizes of from about 250 microns to about 5000 microns.
12. A storable, dry bone implant material comprising an intimate admixture of from about 15 to about 60% by weight of powdered calcium sulfate hemihydrate and from about 40 to about 85% by weight of hydroxylapatite particles.
13. The material of Claim 12 wherein the particles of hydroxylapatite have particle sizes of from about 250 microns to about 5000 microns.
14. The material of Claim 13 consisting essentially of from about 30 to about 40% by weight of powdered calcium sulfate hemihydrate and from about 60 to about 70% by weight of hydroxylapatite particles.
15. A method of filling a bone site with a contour-fitting, rigid-particle bone implant, comprising providing hard filler particles in the form of a moldable plastic bone-implant material composed of a cohesive plastic mixture of the particles and a biocompatible, biodegradable inorganic binder; and filling the bone site with the moldable material to form a contour-fitting implant at the site;
 

where gradual biodegradation of the binder and concomitant ingrowth of surrounding tissue acts to rigidify the implant over a period of several weeks.
16. The method of Claim 15, wherein the hard filler particles comprise hydroxylapatite.

-23-

17. The method of Claim 15, wherein the binder is inorganic cement.

18. The method of Claim 15, wherein the binder comprises calcium sulfate hemihydrate and the filler particles comprise hydroxylapatite particles.

19. The method of Claim 15, wherein the binder consists of calcium sulfate hemihydrate and the filler particles consist essentially of hydroxylapatite particles having a particle size of from 250 microns to about 5000 microns.

20. The method of Claim 15, wherein the providing hard filler particles in the form of a moldable plastic bone-implant material comprises mixing calcium sulfate hemihydrate and hydroxylapatite particles with an amount of sterile biocompatible aqueous liquid sufficient to form a moldable plastic mass.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 87/00548

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC<sup>4</sup>: A 61 L 27/00Minimum Documentation Searched<sup>1</sup>

Classification System 1

Classification Symbols

IPC<sup>4</sup>: A 61 L

Documentation Searched other than Minimum Documentation

to the Extent that such Documents are Included in the Fields Searched<sup>4</sup>ML DOCUMENTS CONSIDERED TO BE RELEVANT<sup>5</sup>

Category 1

Category 2

Category 3

Category 4

Category 5

Category 6

Category 7

Category 8

Category 9

Category 10

Category 11

Category 12

Category 13

Category 14

Category 15

Category 16

Category 17

Category 18

Category 19

Category 20

Category 21

Category 22

Category 23

Category 24

Category 25

Category 26

Category 27

Category 28

Category 29

Category 30

Category 31

Category 32

Category 33

Category 34

Category 35

Category 36

Category 37

Category 38

Category 39

Category 40

Category 41

Category 42

Category 43

Category 44

Category 45

Category 46

Category 47

Category 48

Category 49

Category 50

Category 51

Category 52

Category 53

Category 54

Category 55

Category 56

Category 57

Category 58

Category 59

Category 60

Category 61

Category 62

Category 63

Category 64

Category 65

Category 66

Category 67

Category 68

Category 69

Category 70

Category 71

Category 72

Category 73

Category 74

Category 75

Category 76

Category 77

Category 78

Category 79

Category 80

Category 81

Category 82

Category 83

Category 84

Category 85

Category 86

Category 87

Category 88

Category 89

Category 90

Category 91

Category 92

Category 93

Category 94

Category 95

Category 96

Category 97

Category 98

Category 99

Category 100

Category 101

Category 102

Category 103

Category 104

Category 105

Category 106

Category 107

Category 108

Category 109

Category 110

Category 111

Category 112

Category 113

Category 114

Category 115

Category 116

Category 117

Category 118

Category 119

Category 120

Category 121

Category 122

Category 123

Category 124

Category 125

Category 126

Category 127

Category 128

Category 129

Category 130

Category 131

Category 132

Category 133

Category 134

Category 135

Category 136

Category 137

Category 138

Category 139

Category 140

Category 141

Category 142

Category 143

Category 144

Category 145

Category 146

Category 147

Category 148

Category 149

Category 150

Category 151

Category 152

Category 153

Category 154

Category 155

Category 156

Category 157

Category 158

Category 159

Category 160

Category 161

Category 162

Category 163

Category 164

Category 165

Category 166

Category 167

Category 168

Category 169

Category 170

Category 171

Category 172

Category 173

Category 174

Category 175

Category 176

Category 177

Category 178

Category 179

Category 180

Category 181

Category 182

Category 183

Category 184

Category 185

Category 186

Category 187

Category 188

Category 189

Category 190

Category 191

Category 192

Category 193

Category 194

Category 195

Category 196

Category 197

Category 198

Category 199

Category 200

Category 201

Category 202

Category 203

Category 204

Category 205

Category 206

Category 207

Category 208

Category 209

Category 210

Category 211

Category 212

Category 213

Category 214

Category 215

Category 216

Category 217

Category 218

Category 219

Category 220

Category 221

Category 222

Category 223

Category 224

Category 225

Category 226

Category 227

Category 228

Category 229

Category 230

Category 231

Category 232

Category 233

Category 234

Category 235

Category 236

Category 237

Category 238

Category 239

Category 240

Category 241

Category 242

Category 243

Category 244

Category 245

Category 246

Category 247

Category 248

Category 249

Category 250

Category 251

Category 252

Category 253

Category 254

Category 255

Category 256

Category 257

Category 258

Category 259

Category 260

Category 261

Category 262

Category 263

Category 264

Category 265

Category 266

Category 267

Category 268

Category 269

Category 270

Category 271

Category 272

Category 273

Category 274

Category 275

Category 276

Category 277

Category 278

Category 279

Category 280

Category 281

Category 282

Category 283

Category 284

Category 285

Category 286

Category 287

Category 288

Category 289

Category 290

Category 291

Category 292

Category 293

Category 294

Category 295

Category 296

Category 297

Category 298

Category 299

Category 300

Category 301

Category 302

Category 303

Category 304

Category 305

Category 306

Category 307

Category 308

Category 309

Category 310

Category 311

Category 312

Category 313

Category 314

Category 315

Category 316

Category 317

Category 318

Category 319

Category 320

Category 321

Category 322

Category 323

Category 324

Category 325

Category 326

Category 327

Category 328

Category 329

Category 330

Category 331

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	
Category <sup>1</sup>	Citation of Document, with indication, where appropriate, of the relevant passages
	<p>of calcium sulfate hemihydrate",  see abstract no. 6891q, &amp; J. Appl.  Chem. Biotechnol. 1973, 23(7), 493-500</p> <p>1,6</p>

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/US 87/00548 (SA 16684)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 07/07/87

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NL-A- 8304129	01/07/85	None	
US-A- 4619655	28/10/86	None	
EP-A- 0159089	23/10/85	NL-A- 8401061	01/11/85

For more details about this annex :  
see Official Journal of the European Patent Office, No. 12/82

~~scribbled out text~~

hydroxyapatite 250-5000µ  
250-2000µ preferred

---

5/8-6/25

8-9/5